PD-L1 underexpression

Notably, the tracer showed potential in quantifying dynamic changes in PD-L1 expression during immunotherapy. Collectively, this study confirms that [68Ga]Ga-MRCP can specifically target PD-L1, highlighting its potential for dynamically monitoring PD-L1 expression during immunotherapy.

P1/2, N=226, Terminated, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Terminated; Lack of clinical benefit

In this multiracial TMA of CRC, in a robust multivariable model, following REMARK guidelines, we validate our prior findings that low expression of both B7-H3 and PD-L1 is prognostic for OS among patients with mCRC. Given the rapid proliferation of B7-H3 targeted drug development in clinical trials, these findings may help create a platform for future research to delineate their predictive role in a bespoke therapeutic approach.

First-line immunotherapies-based therapy was cost-effective in metastatic NSCLC with PD-1 lower than 1% in China but not in the USA. Nivolumab plus ipilimumab-based was identified as the most favorable first-line immunotherapy in the USA, while pembrolizumab plus chemotherapy was preferred in China.

Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.

ICIs show manageable safety but limited efficacy in unselected pediatric CNS tumors. Durable benefit is most evident in RRD/hypermutant biology and possibly PD-L1-high niches (e.g., some low-grade gliomas and CNS-GCT). Future trials should be biomarker-driven and pair ICIs with priming combinations (e.g., radiation, epigenetic modulators, metronomic chemotherapy) to convert "cold" tumors into responders.

P1/2, N=226, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting | N=366 --> 226 | Trial completion date: May 2028 --> Jun 2026 | Trial primary completion date: May 2028 --> Jun 2026

Taken together, this study demonstrates the prognostic value of the TIME using the three widely available markers CD3, CD8, and PD-L1 in PSCC. Furthermore, it provides additional evidence for a survival benefit of p16INK4A positive cases, compared to p16INK4A negative cases.

Nevertheless, SH2D1A remained significantly enriched in tumors that responded to ICIs and was associated with improved survival outcomes, outperforming CD3, CD8 and PD-L1. In conclusion, these results suggest that SH2D1A provides information beyond established immune infiltration- and exhaustion-related markers, supporting further investigation of its potential role in biomarker-guided prediction of ICI response in melanoma.

Urgent systemic chemotherapy (nanoparticle paclitaxel, carboplatin, 5-FU) was initiated, followed by addition of toripalimab...Early recognition and prompt initiation of chemo-immunotherapy can stabilize airway compromise and induce rapid response in tracheal SCC. However, aggressive biology mandates close follow-up and individualized, multidisciplinary management.

Single-cell transcriptional profiling was performed on immune cells in PD-L1-low Lewis lung carcinoma (LLC) treated with cyclophosphamide (CTX) and/or anti-PD-1 antibodies...PD-1 blockade synergizes with cytotoxic chemotherapy to diversify and expand PD-1 lineage-traced CTL clonotypes, driving robust antitumor immunity. Thus, our fate-mapping system is a valuable tool to search for immune cells responsive to ICI therapy.

These findings showed that NSD2 inhibits the progression of HCC by inhibiting the expression of PD-L1 through OXPHOS. Our results identify NSD2 as a tumor suppressor in the development of HCC.